Übersicht
- Teva Pharmaceutical IndustriesAktie883035
- Teva Pharmaceutical IndustriesAktie906517
- Teva Pharmaceutical Unternehmensanleihe 6,15 % bis 02/36AnleiheA0GMZX
- Teva Pharmaceutical Unternehmensanleihe 6,00 % bis 04/24AnleiheA19Z32
- Teva Pharmaceutical Unternehmensanleihe 6,00 % bis 01/25AnleiheA280F4
- Optionsscheine auf Teva Pharmaceutical IndustriesOpt.schein426
- Knock-Outs auf Teva Pharmaceutical IndustriesKnock-Out420
- Zertifikate auf Teva Pharmaceutical IndustriesZertifikat368
- UroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNachricht03.04.24
- Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to HumiraNachricht24.02.24
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)Nachricht16.04.24
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNachricht02.05.24
- Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNachricht11.04.24
- Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual MeetingNachricht20.02.24
- Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO (deutetrabenazine) TabletsNachricht16.04.24
- New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY (risperidone) Extended-Release Injectable Suspension at SIRS 2024Nachricht06.04.24
- Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateNachricht04.04.24
- Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in ChinaNachricht26.02.24
- Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementNachricht01.04.24
- Teva to Present at the 2024 Bank of America Healthcare ConferenceNachricht03.05.24
- Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024Nachricht09.04.24
Forum
Nachrichten
07.05.24 | Nachricht | |
06.05.24 | Nachricht | |
05.05.24 | Nachricht | |
04.05.24 | Nachricht | |
03.05.24 | Nachricht |